{"nctId":"NCT01012765","briefTitle":"Effect of Indacaterol on Inspiratory Capacity (IC)","startDateStruct":{"date":"2009-11"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":173,"armGroups":[{"label":"Indacaterol - placebo - tiotropium","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Tiotropium","Drug: Placebo"]},{"label":"Placebo - Tiotropium - Indacaterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Tiotropium","Drug: Placebo"]},{"label":"Tiotropium - indacaterol - placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Tiotropium","Drug: Placebo"]},{"label":"Placebo - indacaterol - tiotropium","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Tiotropium","Drug: Placebo"]},{"label":"Indacaterol - tiotropium - placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Tiotropium","Drug: Placebo"]},{"label":"Tiotropium - placebo - indacaterol","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Tiotropium","Drug: Placebo"]}],"interventions":[{"name":"Indacaterol","otherNames":[]},{"name":"Tiotropium","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Co-operative outpatients with a diagnosis of COPD (moderate as classified by the GOLD Guidelines, 2008) and including:\n\n  * Smoking history of at least 10 pack years\n  * Post-bronchodilator FEV1 \\<80% and â‰¥50% of the predicted normal value (Visit 2).\n  * Post-bronchodilator FEV1/forced vital capacity (FVC) \\<70% (Visit 2).\n\nExclusion Criteria:\n\n* Patients who received any corticosteroid (including inhaled) for 3 months prior to screening\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peak Inspiratory Capacity (IC) After 21 Days of Treatment","description":"IC was measured with spirometry conducted according to internationally accepted standards. Peak IC was defined as the maximum IC of the mean over the 3 values which were measured each at 30min, 2 hour, 3 hour and 4 hour post dose by body plethysmography. Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.69","spread":null},{"groupId":"OG001","value":"2.48","spread":null},{"groupId":"OG002","value":"2.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough IC After 20 Days of Treatment","description":"Trough IC was measured with spirometry conducted according to internationally accepted standards. Trough IC was calculated as the mean of the three measurements of pre-dose body plethysmography (days 21, 55 and 89). Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":null},{"groupId":"OG001","value":"2.28","spread":null},{"groupId":"OG002","value":"2.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Residual Volume (RV) After 21 Days of Treatment","description":"Peak RV was measured with spirometry conducted according to internationally accepted standards. Peak RV was calculated as the Total Lung Capacity minus the maximum of the three Inspiratory Vital Capacity measurements which were measured each at 30 min, 2 hours, 3 hours and 4 hours post dose (at days 21, 55 and 89). Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.77","spread":null},{"groupId":"OG001","value":"4.17","spread":null},{"groupId":"OG002","value":"3.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Total Lung Capacity (TLC) After 21 Days of Treatment","description":"TLC was measured with spirometry conducted according to internationally accepted standards. Peak TLC was calculated as the mean of the three Functional Residual Capacity peak measurements plus the mean of the three Inspiratory Capacity measurements which were measured each at 30 min, 2 hours, 3 hours and 4 hours post dose (at days 21, 55 and 89). Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":null},{"groupId":"OG001","value":"7.38","spread":null},{"groupId":"OG002","value":"7.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Residual Volume/Peak Total Lung Capacity (RV/TLC) Ratio After 21 Days of Treatment","description":"Peak RV/TLC ratio was measured with spirometry conducted according to internationally accepted standards. Peak RV/TLC was defined as the peak RV/peak TLC. Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.57","spread":null},{"groupId":"OG002","value":"0.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Specific Airway Resistance (sRaw) After 21 Days of Treatment","description":"Peak sRaw was measured with spirometry conducted according to internationally accepted standards. Peak sRaw was the mean of the three measurements which were measured each at 30 min, 2 hours, 3 hours and 4 hours post dose (at days 21, 55 and 89). Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":null},{"groupId":"OG001","value":"3.08","spread":null},{"groupId":"OG002","value":"2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 30 Minutes Post-dose After 21 Days of Treatment","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. FEV1 was measured 30 minutes post-dose. Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":null},{"groupId":"OG001","value":"1.68","spread":null},{"groupId":"OG002","value":"1.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) After 20 Days of Treatment","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. FEV1 was measured pre-dose after 20 days of treatment. Analysis of variance model was used with the factors: center, period, treatment, and patients within center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null},{"groupId":"OG001","value":"1.61","spread":null},{"groupId":"OG002","value":"1.78","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":118},"commonTop":["NASOPHARYNGITIS","BACK PAIN","HEADACHE","DYSPNOEA","COUGH"]}}}